Neuraxis reports strong fourth quarter 2024 financial results driven by a 43% increase in revenues

Carmel, ind., march 20, 2025 (globe newswire) -- neuraxis, inc. (“neuraxis,” or the “company”) (nyse american: nrxs), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the fourth quarter and fiscal year 2024 for the period ended december 31, 2024.

NRXS Ratings Summary

NRXS Quant Ranking